Congress One

The GRATS Act (S. 4287) was introduced in the Senate on April 14, 2026. Because the bill text has not yet been published, there is currently no official information available regarding its specific provisions, legal mechanisms, or intended policy goals. As a result, it is not possible to provide a summary of what the bill would do, who it would affect, or its potential impact on individuals. The bill has been referred to the Senate Committee on Finance, where it awaits further review and the release of legislative language.

S.J.Res. 178 is a joint resolution that seeks to overturn a recent decision by the Consumer Financial Protection Bureau (CFPB). Specifically, it aims to block the CFPB’s withdrawal of a rule known as "Procedures for Supervisory Designation Proceedings." If passed, this resolution would effectively reinstate the previous procedures that the CFPB had decided to remove. These procedures dictate how the agency identifies and oversees non-bank financial companies, such as certain fintech firms or mortgage lenders, to ensure they comply with consumer protection laws. This bill does not directly change the laws governing individual consumers, nor does it alter the fundamental authority of the CFPB to regulate financial institutions. It is a procedural measure focused on the internal administrative rules the agency must follow when designating companies for supervision. Because the official text of the rule being withdrawn is not provided in the metadata, the specific impact on the oversight process remains limited to what is described in the resolution's title.

H.Res. 1007 is a non-binding resolution that expresses the House of Representatives' position on the role of the House Committee on Financial Services. It declares that this committee should take the lead in developing public policy regarding how artificial intelligence (AI) is used within the financial and housing sectors. This resolution does not create new laws, regulations, or requirements for businesses or individuals. Instead, it serves as a formal statement of intent regarding which congressional committee should oversee future legislative discussions about AI in these specific industries. Because this is a "sense of the House" resolution, it does not change any existing rules, grant new powers to federal agencies, or impose mandates on the public. It is a procedural step intended to organize how Congress handles future AI-related policy.

H.J.Res. 90 is a resolution that seeks to overturn a 2024 guidance document issued by the Commodity Futures Trading Commission (CFTC). This guidance currently provides standards for exchanges that list "voluntary carbon credit" derivative contracts, which are financial products tied to carbon offset projects. If passed, this resolution would nullify the CFTC’s guidance, meaning the specific criteria the agency set for these financial products would no longer be in effect. This primarily affects the financial exchanges that list these contracts and the companies that trade them, rather than individual retail consumers. This resolution does not ban carbon credits or carbon trading itself. It specifically targets the regulatory framework the CFTC established to oversee how these financial products are listed on public exchanges.

S.J.Res. 36 is a resolution that seeks to overturn a recent rule issued by the Consumer Financial Protection Bureau (CFPB). If passed, this resolution would nullify the CFPB’s regulation that currently prevents medical debt from being included on consumer credit reports. The rule being challenged prohibits creditors and credit reporting agencies from using medical debt information when deciding whether a person is eligible for credit. If this resolution is enacted, the CFPB rule would be canceled, allowing medical debt to once again appear on credit reports and be considered by lenders. This resolution does not change the underlying laws regarding how medical debt is billed or collected by healthcare providers. It specifically addresses the regulatory authority of the CFPB to restrict the use of medical information in credit reporting.